1. Home
  2. MLTX vs GSBD Comparison

MLTX vs GSBD Comparison

Compare MLTX & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoonLake Immunotherapeutics

MLTX

MoonLake Immunotherapeutics

HOLD

Current Price

$15.69

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

GSBD

Goldman Sachs BDC Inc.

HOLD

Current Price

$9.26

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLTX
GSBD
Founded
2021
2012
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MLTX
GSBD
Price
$15.69
$9.26
Analyst Decision
Buy
Sell
Analyst Count
9
1
Target Price
$22.22
$9.00
AVG Volume (30 Days)
2.3M
1.5M
Earning Date
02-25-2026
02-26-2026
Dividend Yield
N/A
13.91%
EPS Growth
N/A
69.72
EPS
N/A
1.14
Revenue
N/A
$383,307,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.06
Revenue Growth
N/A
N/A
52 Week Low
$5.95
$8.92
52 Week High
$62.75
$13.45

Technical Indicators

Market Signals
Indicator
MLTX
GSBD
Relative Strength Index (RSI) 51.98 44.84
Support Level $14.47 $9.08
Resistance Level $16.69 $9.40
Average True Range (ATR) 0.88 0.18
MACD -0.17 0.00
Stochastic Oscillator 49.79 36.40

Price Performance

Historical Comparison
MLTX
GSBD

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: